 |
text only |
|
|||||||||||||||||||||||||||||
Professional Profile
Research Interests: -Cancer chemoprevention and anti-cancer drug discovery -High Content and High Throughput Screening -Assay Development for Laboratory Automation Honors, Professional Organizations, and Achievements: -Member, American Association for Cancer Research, 2005-present -Member, Society for Laboratory Automation and Screening, 2006-present -Member, American Society of Pharmacology & Experimental Therapeutics, 2009-present Education: -Postdoctoral Fellow, University of Alabama at Birmingham, 2004 -Postdoctoral Fellow, Southern Research Institute, 2004-2006 -Ph.D., Pathology, University of Alabama at Birmingham, 2003 -B.S., Natural Sciences, University of Alabama at Birmingham, 1994 Professional Appointments: -Postdoctoral Fellow, Department of Pathology, University of Alabama at Birmingham, 2003-2004 -Postdoctoral Fellow, Cancer Therapeutics Department, Drug Development Division, Southern Research Institute; Birmingham, AL, 2004-2006 -Associate Research Biologist; Biochemistry and Molecular Biology, Drug Discovery Division, Southern Research Institute, 2006-2010 -Research Biologist; Biochemistry and Molecular Biology, Drug Discovery Division, Southern Research Institute, 2010-2011 -Research Assistant Professor of Oncologic Sciences, Drug Discovery, Mitchell Cancer Institute, University of South Alabama, 2011-present Scientific Focus: Cancer chemoprevention and anti-cancer drug discovery, high content and high throughput screening, and assay development for laboratory automation. Selected Publications: 1. Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y, Piazza GA. 2011. Inhibition of PDE5 by Sulindac Sulfide Selectively Induces Apoptosis and Attenuates Oncogenic Wnt/{beta}-Catenin-Mediated Transcription in Human Breast Tumor Cells.. Cancer Prev Res;4(8):1275-84. 2. Li HF, Keeton A, Vitolo M, Maddox C, Rasmussen L, Hobrath J, White EL, Park BH, Piazza G, Kim JS, Waldman T. 2011 A High-Throughput Screen with Isogenic PTEN+/+ and PTEN-/- Cells Identifies CID1340132 as a Novel Compound That Induces Apoptosis in PTEN and PIK3CA Mutant Human Cancer Cells.J Biomol Screen. 16(4):383-93. 3. Bortoff KD, Keeton AB, Franklin JL, Messina JL. 2010 Anti-Inflammatory Action of Insulin via Induction of Gadd45-ß Transcription by the mTOR Signaling Pathway. Hepat Med 2001(2):79-85. 4. Tinsley HN, Gary BD, Thaiparambil J, Li N, Lu W, Li Y, Maxuitenko YY, Keeton AB, Piazza GA. 2010 Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res. 3(10):1303-13. 5. Gabriela Chiosis and Adam B. Keeton. 2009. Assay for Isolation of Inhibitors of Her2-Kinase. Methods of Molecular Biology: Cell-Based Assays for High-Throughput Screening, 486: 139-149. 6. Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC, Piazza GA. 2009 Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther. 8(12):3331-40. 7. Abadi AH, Abouel-Ella DA, Ahmed NS, Gary BD, Thaiparambil JT, Tinsley HN, Keeton AB, Piazza GA. 2009. Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents. Arzneimittelforschung, 59(8):415-21. 8. Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Mathew B, Thaiparambil J, Coward L, Gorman G, Li Y, Sani B, Hobrath JV, Maxuitenko YY, Reynolds RC. 2009. A Novel Sulindac Derivative That Does Not Inhibit Cyclooxygenases but Potently Inhibits Colon Tumor Cell Growth and Induces Apoptosis with Antitumor Activity. Cancer Prev Res, 2(6):572-80. 9. Franklin JL, Keeton AB, Bortoff KD, Messina JL. 2008. Insulin Dependant Gene Expression of Heat Shock Protein 60 in H4IIE Hepatoma Cells. Int J Clin Exp Med, 1(1):89-97. 10. Lu, W, Tinsley, HN, Keeton A, Qu Z, Piazza GA, Li Y. 2009. Suppression of Wnt/beta-catenin Signaling Inhibitors Prostate Cancer Cell Proliferation. Eur. J. Pharmacol, 603:8-14. 11. WL Bennett, AB Keeton, S Ji, J Xu, JL Messina. 2007. Insulin regulation of growth hormone receptor gene expression: involvement of both the PI-3 kinase and MEK/ERK signaling pathways. Endocrine, 32(2):219-26. 12. J. Xu, A.B. Keeton, J.L. Franklin, X. Li, D.Y. Venable, S.J. Frank and J.L. Messina. 2006. Insulin Enhances Growth Hormone Induction of the MEK/ERK Signaling Pathway. Journal of Biological Chemistry, 281: 982-992. 13. A.B. Keeton, K.D. Bortoff, J.L. Franklin and J.L. Messina 2005. Blockade of rapid versus prolonged ERK1/2 activation has differential effects on insulin-induced gene expression. Endocrinology, 146(6):2716-25. 14. J. Xu, A.B. Keeton and J.L. Messina 2005. Gene 33: a Proliferation-Associated Gene Regulated by EGF and Retinoic Acid in Breast Cancer Cell-Lines. Breast Cancer Research and Treatment, 91(3):207-15. 15. A.B. Keeton and J.L. Messina 2005. Messina. Modulation of Elk-dependent-transcription by Gene33. Journal of Cellular Biochemistry 94(6):1190-8. 16. Y. Ma, B. Toth, A.B. Keeton, L.T. Holland, I.H. Chaudry and J.L. Messina. 2004. Mechanisms of Hemorrhage-induced Hepatic Insulin Resistance: Role of Tumor Necrosis Factor-a. Endocrinology, 145: 5168-5176. 17. A.B. Keeton, J.Xu, J.L. Franklin and J.L. 2004. Messina. Regulation of Gene33 Expression by Insulin Requires MEK-ERK Activation. Biochimica et Biophysica Acta-Gene Structure and Expression, 1679: 248-255. 18. A.B. Keeton, K.D. Bortoff, W.L. Bennett, J.L. Franklin, D.Y. Venable and J.L. Messina. 2003. Insulin Regulated Expression of Egr 1 and Krox20: Dependence on ERK1/2 and Interaction with p38 and PI3 Kinase Pathways. Endocrinology, 144: 5402-5410. 19. A.B. Keeton, M.O. Amsler, D.Y. Venable and J.L. Messina. 2002. Insulin Signal Transduction Pathways and Insulin Induced Gene Expression. Journal of Biological Chemistry, 277: 48565-48573. |
||||
Adam B. Keeton, Ph.D.University of South Alabama - Mobile Alabama 36688-0002 Appointments: Medical, Surgical and Gynecologic Oncology: (251) 665-8000 Radiation Oncology: (251) 445-9615 Administration: (251) 460-6993 For questions or comments Contact Us Date last changed: February 3, 2012 3:55 PM http://www.southalabama.edu/mci/keeton.html |
 |